NasdaqGS - Nasdaq Real Time Price USD

Novavax, Inc. (NVAX)

Compare
12.38 +0.98 (+8.60%)
At close: August 30 at 4:00 PM EDT
12.45 +0.07 (+0.57%)
After hours: August 30 at 7:59 PM EDT
Loading Chart for NVAX
DELL
  • Previous Close 11.40
  • Open 11.45
  • Bid 11.03 x 700
  • Ask 12.44 x 900
  • Day's Range 11.13 - 12.48
  • 52 Week Range 3.53 - 23.86
  • Volume 9,395,199
  • Avg. Volume 9,689,330
  • Market Cap (intraday) 1.982B
  • Beta (5Y Monthly) 1.97
  • PE Ratio (TTM) --
  • EPS (TTM) -2.62
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 20.00

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

www.novavax.com

1,543

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVAX

View More

Performance Overview: NVAX

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVAX
157.92%
S&P 500
18.42%

1-Year Return

NVAX
49.16%
S&P 500
25.59%

3-Year Return

NVAX
94.54%
S&P 500
25.26%

5-Year Return

NVAX
99.68%
S&P 500
93.14%

Compare To: NVAX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVAX

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    1.98B

  • Enterprise Value

    1.16B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.86

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.08

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -29.80%

  • Return on Assets (ttm)

    -10.21%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    987.67M

  • Net Income Avi to Common (ttm)

    -294.33M

  • Diluted EPS (ttm)

    -2.62

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.05B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -97.84M

Research Analysis: NVAX

View More

Company Insights: NVAX

Research Reports: NVAX

View More

People Also Watch